OncoZenge AB (publ) (STO:ONCOZ)

Market Cap	78.80M +19.4%
Revenue (ttm)	5.97M +114.8%
Net Income	-26.17M
EPS	-2.00
Shares Out	27.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,079
Open	2.855
Previous Close	3.005
Day's Range	2.855 - 2.855
52-Week Range	2.855 - 10.280
Beta	1.40
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About OncoZenge AB

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCOZ

Financial Performance

In 2025, OncoZenge AB's revenue was 2.78 million, an increase of 278300.00% compared to the previous year's 1,000. Losses were -15.94 million, 83.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 4, 2026

Data Sources Report a data error